Sabinsa's Curcumin C3 Complex Ingredient Used in UCLA School of Medicine Alzheimer's Disease Study

Study Results Published in Recent Edition of The Journal of Alzheimer's Disease

PISCATAWAY, N.J., October 16, 2006 - Sabinsa Corporation's patented Curcumin C3 Complex(R) ingredient was recently used to elucidate curcuminoids potential mechanism of action in Alzheimer's disease.

The results of this in vitro study, which were published in the October 9, 2006 edition of The Journal of Alzheimer's Disease, found that curcuminoids from Curcumin C3 Complex could boost the body's ability to clear the build up of plaque in the brain that is linked to Alzheimer's disease. Previous research supports that plaque, specifically from amyloid-beta deposits, could be a contributing factor to the development of Alzheimer's disease.

"These initial findings may lead to a new approach in treating Alzheimer's disease by enhancing the natural function of the immune system using curcumin, thus increasing the body's ability to remove plaques that may cause Alzheimer's disease and other forms of dementia," stated Milan Fiala, M.D., researcher, UCLA School of Medicine.

Blood taken from six Alzheimer's disease patients and three healthy controls was isolated for macrophages, cells of the immune system that function in the destruction of foreign antigens. The isolated macrophages were exposed to Curcumin C3 Complex in a cell culture for24 hours, after which time amyloid-beta was introduced. The treated macrophages from the Alzheimer's disease patients showed improved ingestion of amyloid-beta compared to those not treated with curcuminoids. Macrophages from the healthy controls, which were shown to be effectively clearing amyloid-beta, showed no changes with
curcuminoids treatment. For more information refer to UCLA press

"The amount of research being conducted on curcuminoids in different and diversified fields of medicine is staggering, and it is becoming evident from results of basic, preclinical and clinical research that they are some of the most promising food derived compounds for managing inflammatory and degenerative conditions," noted Vladimir Badmaev, M.D., Ph.D., vice president of scientific and medical affairs, Sabinsa Corporation. "Often in studies, the material being tested is not commercially available. However, our Curcumin C3 Complex is available to manufacturers, as well as to consumers through a variety of finished products."

Curcumin C3 Complex is an extract of turmeric standardized to 95 percent curcuminoids. Sabinsa currently holds U.S. patent #5,861,415 for a bioprotectant composition of curcuminoids and related U.S.
patent #6,653,327 for tetrahydrocurcuminoids, naturally occurring decolorized curcuminoids. Curcumin C3 Complex has been certified by NSF International to ensure that it is free of any impurities and contaminants that may be potentially harmful to consumers. Over the past several years, numerous studies have been funded by the National Institutes of Health to investigate the role of curcumin and its derivatives in treatment of patients with cancer. Additionally, M.D.
Anderson Cancer Center at the University of Texas is involved in pre- clinical and clinical research of the anti-cancer mechanism and application of curcuminoids in conditions including lung, breast, multiple myeloma, pancreatic, myelodysplatic syndrome, colon, prostate, head and neck cancers. Recently, Sabinsa's Curcumin C3 Complex was named as the curcuminoids ingredient of choice by M.D.
Anderson Cancer Center. For more information visit

Sabinsa Corporation, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals. Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being.
Over the past nine years, Sabinsa has brought to market more than 50 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher.
For more information visit or stop by Sabinsa's booth #'s 6007/6009 at SupplySide West.

# # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.